Cargando…
FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer
BACKGROUND: Concomitant chemo-radiotherapy is the reference treatment for non-resectable locally-advanced Non-Small Cell Lung Cancer (NSCLC). Increasing radiotherapy total dose in the whole tumour volume has been shown to be deleterious. Functional imaging with positron emission tomography (PET/CT)...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199734/ https://www.ncbi.nlm.nih.gov/pubmed/30352608 http://dx.doi.org/10.1186/s13014-018-1147-2 |
_version_ | 1783365187872489472 |
---|---|
author | Thureau, Sébastien Dubray, Bernard Modzelewski, Romain Bohn, Pierre Hapdey, Sébastien Vincent, Sabine Anger, Elodie Gensanne, David Pirault, Nicolas Pierrick, Gouel Vera, Pierre |
author_facet | Thureau, Sébastien Dubray, Bernard Modzelewski, Romain Bohn, Pierre Hapdey, Sébastien Vincent, Sabine Anger, Elodie Gensanne, David Pirault, Nicolas Pierrick, Gouel Vera, Pierre |
author_sort | Thureau, Sébastien |
collection | PubMed |
description | BACKGROUND: Concomitant chemo-radiotherapy is the reference treatment for non-resectable locally-advanced Non-Small Cell Lung Cancer (NSCLC). Increasing radiotherapy total dose in the whole tumour volume has been shown to be deleterious. Functional imaging with positron emission tomography (PET/CT) offers the potential to identify smaller and biologically meaningful target volumes that could be irradiated with larger doses without compromising Organs At Risk (OAR) tolerance. This study investigated four scenarios, based on (18)FDG and (18)F-miso PET/CT, to delineate the target volumes and derive radiotherapy plans delivering up to 74Gy. METHOD: Twenty-one NSCLC patients, selected from a prospective phase II trial, had (18)FDG- and (18)F-miso PET/CT before the start of radiotherapy and (18)FDG PET/CT during the radiotherapy (42Gy). The plans were based planned on a standard plan delivering 66 Gy (plan 1) and on three different boost strategies to deliver 74Gy total dose in pre-treatment (18)FDG hotspot (70% of SUV(max)) (plan 2), pre-treatment (18)F-miso target (SUV(max) > 1.4) (plan 3) and per-treatment (18)FDG residual (40% of SUV(max)). (plan 4). RESULTS: The mean target volumes were 4.8 cc (± 1.1) for (18)FDG hotspot, 38.9 cc (± 14.5) for (18)F-miso and 36.0 cc (± 10.1) for per-treatment (18)FDG. In standard plan (66 Gy), the mean dose covering 95% of the PTV (D95%) were 66.5 (± 0.33), 66.1 (± 0.32) and 66.1 (± 0.32) Gy for (18)FDG hotspot, (18)F-miso and per-treatment (18)FDG. In scenario 2, the mean D95% was 72.5 (± 0.25) Gy in (18)FDG hotspot versus 67.9 (± 0.49) and 67.9 Gy (± 0.52) in (18)F-miso and per-treatment (18)FDG, respectively. In scenario 3, the mean D95% was 72.2 (± 0.27) Gy to (18)F-miso versus 70.4 (± 0.74) and 69.5Gy (± 0.74) for (18)FDG hotspot and per-treatment (18)FDG, respectively. In scenario 4, the mean D95% was 73.1 (± 0.3) Gy to (18)FDG per-treatment versus 71.9 (± 0.61) and 69.8 (± 0.61) Gy for (18)FDG hotspot and (18)F-miso, respectively. The dose/volume constraints to OARs were matched in all scenarios. CONCLUSION: Escalated doses can be selectively planned in NSCLC target volumes delineated on (18)FDG and (18)F-miso PET/CT functional images. The most relevant strategy should be investigated in clinical trials. TRIAL REGISTRATION: (RTEP5, NCT01576796, registered 15 june 2012) |
format | Online Article Text |
id | pubmed-6199734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61997342018-10-31 FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer Thureau, Sébastien Dubray, Bernard Modzelewski, Romain Bohn, Pierre Hapdey, Sébastien Vincent, Sabine Anger, Elodie Gensanne, David Pirault, Nicolas Pierrick, Gouel Vera, Pierre Radiat Oncol Research BACKGROUND: Concomitant chemo-radiotherapy is the reference treatment for non-resectable locally-advanced Non-Small Cell Lung Cancer (NSCLC). Increasing radiotherapy total dose in the whole tumour volume has been shown to be deleterious. Functional imaging with positron emission tomography (PET/CT) offers the potential to identify smaller and biologically meaningful target volumes that could be irradiated with larger doses without compromising Organs At Risk (OAR) tolerance. This study investigated four scenarios, based on (18)FDG and (18)F-miso PET/CT, to delineate the target volumes and derive radiotherapy plans delivering up to 74Gy. METHOD: Twenty-one NSCLC patients, selected from a prospective phase II trial, had (18)FDG- and (18)F-miso PET/CT before the start of radiotherapy and (18)FDG PET/CT during the radiotherapy (42Gy). The plans were based planned on a standard plan delivering 66 Gy (plan 1) and on three different boost strategies to deliver 74Gy total dose in pre-treatment (18)FDG hotspot (70% of SUV(max)) (plan 2), pre-treatment (18)F-miso target (SUV(max) > 1.4) (plan 3) and per-treatment (18)FDG residual (40% of SUV(max)). (plan 4). RESULTS: The mean target volumes were 4.8 cc (± 1.1) for (18)FDG hotspot, 38.9 cc (± 14.5) for (18)F-miso and 36.0 cc (± 10.1) for per-treatment (18)FDG. In standard plan (66 Gy), the mean dose covering 95% of the PTV (D95%) were 66.5 (± 0.33), 66.1 (± 0.32) and 66.1 (± 0.32) Gy for (18)FDG hotspot, (18)F-miso and per-treatment (18)FDG. In scenario 2, the mean D95% was 72.5 (± 0.25) Gy in (18)FDG hotspot versus 67.9 (± 0.49) and 67.9 Gy (± 0.52) in (18)F-miso and per-treatment (18)FDG, respectively. In scenario 3, the mean D95% was 72.2 (± 0.27) Gy to (18)F-miso versus 70.4 (± 0.74) and 69.5Gy (± 0.74) for (18)FDG hotspot and per-treatment (18)FDG, respectively. In scenario 4, the mean D95% was 73.1 (± 0.3) Gy to (18)FDG per-treatment versus 71.9 (± 0.61) and 69.8 (± 0.61) Gy for (18)FDG hotspot and (18)F-miso, respectively. The dose/volume constraints to OARs were matched in all scenarios. CONCLUSION: Escalated doses can be selectively planned in NSCLC target volumes delineated on (18)FDG and (18)F-miso PET/CT functional images. The most relevant strategy should be investigated in clinical trials. TRIAL REGISTRATION: (RTEP5, NCT01576796, registered 15 june 2012) BioMed Central 2018-10-23 /pmc/articles/PMC6199734/ /pubmed/30352608 http://dx.doi.org/10.1186/s13014-018-1147-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Thureau, Sébastien Dubray, Bernard Modzelewski, Romain Bohn, Pierre Hapdey, Sébastien Vincent, Sabine Anger, Elodie Gensanne, David Pirault, Nicolas Pierrick, Gouel Vera, Pierre FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer |
title | FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer |
title_full | FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer |
title_fullStr | FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer |
title_full_unstemmed | FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer |
title_short | FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer |
title_sort | fdg and fmiso pet-guided dose escalation with intensity-modulated radiotherapy in lung cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199734/ https://www.ncbi.nlm.nih.gov/pubmed/30352608 http://dx.doi.org/10.1186/s13014-018-1147-2 |
work_keys_str_mv | AT thureausebastien fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer AT dubraybernard fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer AT modzelewskiromain fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer AT bohnpierre fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer AT hapdeysebastien fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer AT vincentsabine fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer AT angerelodie fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer AT gensannedavid fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer AT piraultnicolas fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer AT pierrickgouel fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer AT verapierre fdgandfmisopetguideddoseescalationwithintensitymodulatedradiotherapyinlungcancer |